Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Beta Drugs Limited (NSE: BETA), ISIN INE351Y01019 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
BETA last traded at ₹1878.80 (+4.04%), with a 52-week range of ₹990.10 to ₹2807.90 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 58.91%, FIIs 1.37%, DIIs 6.45%, mutual funds 0.00%.
EquiSense Score (ECS): 76/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.